BioSpace News Archive

Allogene Therapeutics, Inc., announced the commencement of an underwritten public offering of $450.0 million of shares of its common stock.

Antibe Therapeutics Inc. is pleased to announce that its lead drug, ATB-346, met the primary endpoint in the Phase 2B dose-ranging, efficacy study.

Company believes District Court decision misinterprets federal law and fails to address important legal requirements of the Administrative Procedure Act

Only PARP Inhibitor to Demonstrate Patient Benefit in a Phase 3 Trial in This Setting

Tool provides electrophysiologists with first-ever local measurement and visualization of tissue response to radiofrequency ablation

TriSalus Life Sciences, a company committed to transforming outcomes for patients with solid tumors, announced the appointment of Rajesh B. Mistry as Chief Financial Officer.

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020. Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effective June 1, 2020. Mr. Cartwright will remain with the Company as an advisor for a transitional

Collaboration includes Development of Manufacturing Processes and to Supply Clinical Trial Material to Support Tonix’s Development of TNX-1800

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced the U.S. Food and Drug Administration has authorized the Company to proceed with a clinical trial of T-COVID, an investigational agent for the treatment of early COVID-19.

via NEWMEDIAWIRE – Progressive Care Inc.,a personalized healthcare services and technology company, is pleased to announce that the Company has selected Atlas Construction and Management LLC for the construction project at 400 Ansin Blvd in Hallandale Beach, FL.